Latest news with #MedicalDevelopmentsInternationalLimited
Yahoo
19-05-2025
- Business
- Yahoo
One Medical Developments International Insider Raised Stake By 42% In Previous Year
From what we can see, insiders were net buyers in Medical Developments International Limited's (ASX:MVP ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Over the last year, we can see that the biggest insider purchase was by insider David Williams for AU$3.3m worth of shares, at about AU$2.07 per share. That means that an insider was happy to buy shares at above the current price of AU$0.59. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was David Williams. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for Medical Developments International There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Medical Developments International insiders own 15% of the company, worth about AU$9.7m. We do generally prefer see higher levels of insider ownership. There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Medical Developments International stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 3 warning signs we've spotted with Medical Developments International (including 1 which is potentially serious). If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
30-04-2025
- Business
- Business Insider
Positive Report for Medical Developments International Limited (MVP) from Bell Potter
Bell Potter analyst Martyn Jacobs upgraded Medical Developments International Limited (MVP – Research Report) to a Buy today and set a price target of A$0.80. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Jacobs is an analyst with an average return of -23.3% and an 11.27% success rate. Currently, the analyst consensus on Medical Developments International Limited is a Hold with an average price target of A$0.71. The company has a one-year high of A$0.94 and a one-year low of A$0.36. Currently, Medical Developments International Limited has an average volume of 286.5K.
Yahoo
21-02-2025
- Business
- Yahoo
Shareholders in Medical Developments International (ASX:MVP) have lost 90%, as stock drops 13% this past week
This month, we saw the Medical Developments International Limited (ASX:MVP) up an impressive 96%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 90%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. With the stock having lost 13% in the past week, it's worth taking a look at business performance and seeing if there's any red flags. View our latest analysis for Medical Developments International Given that Medical Developments International didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last half decade, Medical Developments International saw its revenue increase by 11% per year. That's a fairly respectable growth rate. So the stock price fall of 14% per year seems pretty steep. The market can be a harsh master when your company is losing money and revenue growth disappoints. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Medical Developments International stock, you should check out this free report showing analyst profit forecasts. While the broader market gained around 12% in the last year, Medical Developments International shareholders lost 10%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 14% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Medical Developments International has 3 warning signs (and 2 which make us uncomfortable) we think you should know about. Medical Developments International is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
21-02-2025
- Business
- Yahoo
Shareholders in Medical Developments International (ASX:MVP) have lost 90%, as stock drops 13% this past week
This month, we saw the Medical Developments International Limited (ASX:MVP) up an impressive 96%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 90%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. With the stock having lost 13% in the past week, it's worth taking a look at business performance and seeing if there's any red flags. View our latest analysis for Medical Developments International Given that Medical Developments International didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last half decade, Medical Developments International saw its revenue increase by 11% per year. That's a fairly respectable growth rate. So the stock price fall of 14% per year seems pretty steep. The market can be a harsh master when your company is losing money and revenue growth disappoints. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Medical Developments International stock, you should check out this free report showing analyst profit forecasts. While the broader market gained around 12% in the last year, Medical Developments International shareholders lost 10%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 14% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Medical Developments International has 3 warning signs (and 2 which make us uncomfortable) we think you should know about. Medical Developments International is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
